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ABSTRACT: Introduction: The assisted 6-minute cycle test
(A6MCT) distance was assessed in adults with muscular dystro-
phy (MD). Methods: Forty-eight males, including those with Duch-
enne MD (DMD), limb-girdle MD (LGMD), fascioscapulohumeral
MD (FSHD), and Becker MD (BMD), as well as a group without
MD (CTRL), completed handgrip strength (HGS), lung function
[forced expiratory volume in 1 second (FEV1) and forced vital
capacity (FVC)], body fat, and biceps thickness assessments.
During the A6MCT, ventilation (VE), oxygen uptake (VO2), carbon
dioxide (VCO2), and heart rate (HR) were recorded. Results:
A6MCT and HGS were lower in MD than CTRL subjects. FEV1,
FVC, and biceps thickness were lower in MD than CTRL; lower
in DMD than BMD, LGMD, and FSHD; but were not different
between BMD, LGMD, and FSHD. A6MCT correlated with HGS,
FEV1, FVC, body fat, VO2, VCO2, HR, and VE (r50.455–0.708)
in pooled BMD, LGMD, and FSHD participants. Discussion: A
shorter A6MCT distance in adult males with MD was attributable
to HGS and lung function. The A6MCT is appropriate for assess-
ment of physical function in adults with MD.
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Muscular dystrophy (MD) is a heterogeneous group
of neuromuscular disorders characterized by a
genetic predisposition to an absence or reduction in
proteins within and around the sarcolemma.1 Duch-
enne muscular dystrophy (DMD), Becker muscular
dystrophy (BMD), limb-girdle muscular dystrophy
(LGMD),2,3 and facioscapulohumeral muscular dys-
trophy (FSHD) 4 all have distinct loci of impairments
within the proteins of the sarcoglycan complex, which
are reflected by distinct functional impairments in
terms of location and severity of progression.1 They
are, however, all similar in that they are associated
with a loss of physical function.5 Ambulatory status
and walking speed are frequently used as indicators
of progression and severity of various MDs.6–8 The
association between timed walking tests and the pro-
gression of numerous neuromuscular conditions
makes them an essential, yet simple means of moni-
toring and screening.9 Within MD, the 6-minute walk
test (6MWT) is advocated based on its reliability, sen-
sitivity, and approximation to numerous physiological
outcome measures as well as its position as one of the
best single measures of independence and func-
tion.6,7 Although suitable for the early years of DMD,
and for some ambulatory MDs, the capacity to com-
plete a 6MWT, is not possible in a large percentage of
adults with MD. Indeed, the 6MWT, although advo-
cated as a test of functional capacity in MD,10 would
be impossible in 55%, 18%, 36%, and 100% of our
previously described adult participants with LGMD,
FSHD, BMD, and DMD, respectively.11 In search of
an alternative functional test, Jansen et al.12 validated
the assisted 6-minute cycle test (A6MCT) against the
6MWT in children with DMD, and found a high
degree of reliability and validity.
The A6MCT, was developed in children with MD
as a submaximal endurance test for those who may
be wheelchair-dependent, or lack the confidence or
capacity to complete timed walking tests.12 The use
of a motor-assisted device, set at minimal resistance
and speed (7HZ), meant that even those with lim-
ited upper limb function could contribute some
active torque, however minimal, over the 6-minute
period. In contrast, those children who maintained
upper limb function, even in DMD, could produce
an active torque, and accelerate the arm crank to
produce a good discriminatory test between the
most impaired of those with MD.12
At present, there are no normative A6MCT data
from adults with MD. In non-ambulatory adults with
MD, there are limited data on muscle function, partic-
ularly from a power-assisted task that would be sensi-
tive to those who were most impaired. Unlike the
6MWT, which is known to be associated with knee
extension strength in children with DMD,7 and oxygen
uptake (VO2) and lung function in cardiorespiratory
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conditions,13–15 the A6MCT is yet to be presented
alongside physiological parameters such as muscle size
and strength and lung function in adults with MD.
Thus, the aim of this study was to: (1) compare
A6MCT distance and cardiorespiratory function in
adult males with MD; and (2) identify whether
A6MCT is associated with physiological outcomes
such as muscle strength and size and lung function.
We hypothesized that A6MCT distance would
reflect previous patterns of muscular and respira-
tory impairment,11 such that all MDs would per-
form lower than CTRL subjects, with DMD and
BMD patients completing the least distance fol-
lowed by LGMD and FSHD patients; consistent
with data from the 6MWT,7 we hypothesized that
measures of muscle and respiratory function would
correlate with A6MCT distance.
METHODS
Forty-eight adult males volunteered for this study (Table
1), 38 of whom had previously been diagnosed with either
FSHD, BMD, LGMD, or DMD; the remaining 10 had no form
of MD and formed a control (CTRL) group. MD participants
were classified as ambulatory or non-ambulatory, and were
graded for arm and leg function using Brooke and Vignos
scales, respectively,16 by a chartered physiotherapist. MD par-
ticipants were recruited from, and tested at, The Neuromus-
cular Centre (Winsford, UK). All MD participants were
receiving weekly physiotherapy treatment involving passive
mobility activities lasting approximately 1 hour. The CTRL
subjects, free from neurological disorders and otherwise in
good health, were recruited from the broader community of
The Neuromuscular Centre (none were related to MD partici-
pants), or were staff/students of MMU. Control participants
self-reported being sedentary, undertaking <1 hour of recrea-
tional physical activity; none of the participants were under-
taking any structured or regular exercise training regimens.
Two additional adult males, with DMD and BMD, were
unable to complete the testing protocol. Their reasons for
withdrawal were: (1) upper limb contractures making the
hand cycle range of motion impossible to complete; and (2)
respiratory insufficiency to overcome the face mask used for
expired gas analysis. The data presented here represent the
48 adult males who completed all procedures.
All procedures conformed to the standards set by the
latest revision of the Declaration of Helsinki,17 and were
approved by the local ethics committee of Manchester Met-
ropolitan University. Written informed consent was
obtained from all participants before inclusion.
Procedures. All participants were tested on a single visit to
The Neuromuscular Centre. The testing session was con-
ducted in the following order: anthropometry; body composi-
tion assessment; lung function; grip strength; questionnaires;
resting energy expenditure; and A6MCT. The same equip-
ment was used for both population groups, with the excep-
tion of the seated scales for body mass measures in non-
ambulatory MD participants.
Anthropometric Measures. All participant heights were
calculated as point-to-point arm span (index finger, elbow,
shoulder, and across midline), using a 2-m tape measure. To
account for the known discrepancy between standing height
and arm-span measures, a correction was applied using regres-
sion data from adult males, with the known error of making
this correction of 3.5%.18 Participant height is presented as
this corrected value. In a sample of MD participants who
could complete arm-span and standing height (n5 12) assess-
ment, arm span was not different from height, with an error
of 7.97 cm (4.5%) and intraclass correlation (ICC) of 0.67.
Estimating height from arm span within this sample, gave an
error of 2.58 cm (1.4%), and ICC 0.66. In the control group,
body mass was measured by digital scales (Model 873; Seca,
Hamburg, Germany). MD participants were weighed in seated
scales (6875; Detecto, Webb City, Missouri). The weights of
slings, shoes, splints, etc., were subtracted from gross weight
after weighing separately.
Table 1. Participants’ demographics
CTRL FSHD LGMD BMD DMD
Number of participants 10 9 11 9 9
Age (years) 29.8 (10.7) 43.9 (13.7)* 45.1 (9.2)* 37.4 (7.6) 22.7 (3.0)†‡§
Age range (years) 19–51 25–60 30–60 27–51 18–26
Stature (m) 1.79 (0.09) 1.81 (0.04) 1.76 (0.08) 1.73 (0.11) 1.72 (0.10)
Mass (kg) 76.2 (13.8) 83.5 (14.1) 94.3 (14.2) 88.8 (24.2) 74.7 (15.4)
Body fat (%) 15.2 (5.1) 22.9 (6.8) 32.4 (7.8)*,† 32.1 (9.1)*,† 32.4 (2.9)*,†
BMI (kg/m2) 24.1 (3.7) 24.0 (5.0) 29.9 (4.2)‡ 31.6 (10.9) 25.5 (6.0)
Lean mass (kg) 67.4 (10.4) 62.9 (12.9) 63.8 (7.6) 59.0 (12.3) 50.7 (10.0)*
PASIPD — 11.7 (9.0) 14.8 (11.6) 5.7 (4.8) 4.1 (4.8)§
Biceps thickness (mm) 39.6 (5.0) 31.2 (10.1) 30.7 (6.7) 26.7 (9.8)* 26.4 (8.9)*
Ambulatory (%) 100 89 36 22 0
Brooke scale — 1 (1–3) 3 (1–5)† 3 (2–4)† 6 (4–6)†‡§
Vignos scale — 2 (1–9) 9 (2–9)† 9 (4–9)† 9 (9)†
Data are presented as mean (SD), except for Brooke and Vignos scales, which are presented as mean (range). CTRL, control; LGMD, limb girdle muscular
dystrophy; FSHD, fascioscapulohumeral; BMD, Becker muscular dystrophy; DMD, Duchenne muscular dystrophy; BMI, body mass index; PASIPD, Physi-
cal Activity Score for Individuals with Physical Disability.
*Significant difference vs. CTRL (P< 0.05).
†Significant difference vs. FSHD (P< 0.05).
‡Significant difference vs. BMD (P< 0.05).
§Significant difference vs. LGMD (P< 0.05).
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Body Composition. Fat mass and fat-free mass (FFM)
were measured using a bioelectrical impedance (BIA)
device (Model 1500; Bodystat, Isle of Man, UK) with adhe-
sive electrodes placed on the right hand (between styloid
process of ulna and radius) and foot (between the medial
and lateral malleoli). Body composition, FFM, and fat mass
were determined using the proprietary equations within the
BIA device. BIA has previously been used within DMD pop-
ulations19 and has been shown to be valid and reliable com-
pared with dual-energy X-ray absorptiometry (DXA) in both
normal and overweight populations.20,21 In addition, the
portability of the BIA makes it a viable alternative to DXA
in subjects with limited mobility.22
Biceps Thickness. Biceps thickness was measured in all
participants, consistent with previously established meth-
ods.23 Participants were seated with their dominant arm hang-
ing, relaxed at their side. The medial and lateral boundaries
of the biceps were identified in the transverse plane using B-
mode ultrasound (MyLab Gamma; Esaote, Reading, Berks.,
UK) with a 7.5-MHZ linear-array probe. Thickness measure-
ments (distance between the superficial and deep aponeuro-
sis) were taken on the mid-sagittal line of the biceps at 60% of
the upper arm length (the distance from the acromion pro-
cess of the scapular to the lateral epicondyle of the humerus).
Three measurements were made at the proximal, middle,
and end of the displayed image, from 3 images of the biceps.
The biceps thickness presented is the average of these
measures.
Lung Function. Forced vital capacity (FVC) and forced
expiratory volume in 1 second (FEV1) were measured using
an electronic spirometer (Pneumotrac; Vitalograph, Bucks.,
UK). All participants performed the measurements seated
and wearing a nose clip. The best performance of 3 trials is
reported. The validity of the electronic vitalograph has been
established in healthy and clinical populations.24
Grip Strength. A digital handgrip dynamometer (Jamar
Plus; Patterson Medical, Warrenville, Illinois) was used to
measure grip strength. Of those participants who could pro-
duce a measureable grip force (2 DMD participants produced
no grip strength), 3 maximal attempts were made. Partici-
pants performed all 3 of the 5-s maximal grip efforts while in
a seated position using the dominant hand and with the arm
in a relaxed position at their side. All 3 tests were separated
by 1 minute, and the peak reading was recorded. Test–retest
reliability has been reported as high, with low measurement
error.25
Physical Activity Questionnaire. MD participants com-
pleted a disability-specific physical activity questionnaire
[i.e., the Physical Activity Score for Individuals with Physical
Disabilities (PASIPD) questionnaire].26 The PASIPD ques-
tionnaire encompasses a lower activity threshold and has
been validated as a reliable outcome measure for physical
activity in individuals with disability.27
Expired Gas Analysis. Expired gas analysis was per-
formed at rest and during the A6MCT using a face mask
and volume sensor assembly (Metalyser; Cortex, Leipzig,
Germany). Fractional concentrations of oxygen and carbon
dioxide were measured via a capillary line from the face
mask. The gas analyzer and volume transducer were cor-
rected for ambient conditions (pressure and temperature)
and calibrated before each test. All participants were seated
during resting and exercising measurements.
Resting Measures. Resting measures were recorded for 1
minute after 20 minutes of seated rest with the face mask
attached. This duration was chosen as it allows a sufficient pla-
teau in respiration to acquire reliable data.28 Outcome mea-
sures for the expired gas analysis are described in what follows.
A6MCT. The A6MCT was conducted in accordance with
the protocol of Jansen et al.12; however, only upper limb test-
ing was performed as this allowed a wider range of partici-
pants to be recruited. Participants performed the A6MCT
using a motor-assisted hand bike mobility trainer
(MOTOmed; Viva2, Reck, Germany), with a zero load speed
of 7 rpm, consistent with previously adopted methods.12 Par-
ticipants were instructed to cycle as fast as possible for 6
minutes, while receiving verbal encouragement. Those MD
participants who were unable to produce an active torque
throughout the 6 minutes were encouraged to rest, allowing
the hand bike to passively move their arms, until they were
able to continue producing an active torque. The primary
outcome measure of the A6MCT was cycle distance. Heart
rate (HR) was monitored by short-range telemetry (Polar,
Kempele, Finland) throughout the exercise test every 5 sec-
onds and is presented averaged over each minute of exercise.
Blood lactate was assessed using fingertip capillary sam-
ples (Accutrend Plus; Roche Diagnostics, Ltd., London,
UK) at 5 minutes before (BLapre), and immediately after
A6MCT (BLapost).
One-minute averages for rest, and for each minute of
the A6MCT, were taken from the breath-by-breath samples
and are presented as standard temperature, pressure, and
dry volumes, where relevant. Reported outcome measures
include: pulmonary ventilation (VE); oxygen uptake (VO2);
carbon dioxide output (VCO2); and respiratory quotient.
VO2 and VCO2 are presented relative to body mass.
Statistics. All analyses were performed using IBM SPSS
version 24 software (IBM SPSS, Armonk, New York). Paramet-
ric assumptions of normal distribution were confirmed using
the Shapiro-Wilk test (P> 0.05) in all dependent variables,
except for total A6MCT distance (P< 0.05). Differences
between the groups were analyzed using a one-way analysis of
variance (ANOVA) with either Tukey or Games–Howell post-
hoc test, depending on whether variance was homogeneous
(Levene’s test, P> 0.05) or non-homogeneous (Levene’s test,
P< 0.05), respectively. Variables that violated normal distribu-
tion were compared between groups using the Kruskal–Wallis
test, with post-hoc Mann–Whitney U-test pairwise comparisons
when appropriate.
Where comparisons were made at 1-minute intervals over
the A6MCT, a 33 6 ANOVA was performed. Tukey post-hoc test
was conducted whendever group differences were observed.
With all post-hoc comparisons, unless otherwise stated,
differences are indicated in one direction of comparison;
that is, if a group performed “worse” than any other, the P-
value is reported, or denoted with the relevant superscript.
Correlations were performed using grouped data
(pooled FSHD, LGMD, and BMD) in the conditions that
showed no between-group differences for dependent varia-
bles. The Pearson correlation was performed because these
data were normally distributed.
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All data are reported as mean (standard deviation). Sta-
tistically significant differences and/or associations were
accepted at a 0.05.
RESULTS
Demographic, Anthropometric, and Body Composition
Measures. As shown in Table 1, DMD participants
were younger than LGMD, BMD, and FSHD partici-
pants. Compared with CTRL, LGMD and FSHD
were older. DMD and BMD showed no age differ-
ence compared with CTRL. There were no differ-
ences in stature or body mass between groups.
LGMD, BMD, and DMD had higher body fat per-
centage than FSHD and control participants. Lean
mass was lower in DMD than CTRL subjects, with
no lean mass differences observed between other
groups.
Biceps Thickness. Compared with CTRL, DMD
and BMD had smaller biceps thickness. There was
no difference between MD populations for biceps
thickness. LGMD and FSHD biceps thicknesses
were not different from those of CTRL (Table 1).
Physical Activity. Physical activity was lower in
DMD than LGMD (Table 1); there was no differ-
ence between the other MD groups.
Lung Function. Compared with CTRL, FEV1 was
lower in FSHD, LGMD, and DMD. Compared with
the other MD groups, DMD had a lower FEV1. FVC
was lower than that for CTRL in all MD groups. DMD
had a lower FVC than the other MD groups (Table 2).
Grip Strength. Compared with CTRL, grip strength
was less in all MD groups. DMD had lower grip
strength than LGMD and FSHD (Table 2).
A6MCT Distance. A6MCT distance was shorter in
FSHD, LGMD, BMD, and DMD when compared
with CTRL. The DMD A6MCT distance was shorter
when compared with FSHD, LGMD, and BMD.
There was no difference in A6MCT distance bet-
ween BMD, LGMD, and FSHD (Table 2).
A6MCT VO2. Throughout the A6MCT, VO2 in
DMD, BMD, LGMD, and FSHD was lower than in
CTRL. VO2 during the A6MCT was lower in DMD
compared with other MD groups. There was no
difference in VO2 during the A6MCT at any time-
point between BMD, FSHD, or LGMD (Fig. 1A).
A6MCT VCO2. Throughout the A6MCT, VCO2 was
lower than CTRL than in DMD, BMD, LGMD, and
FSHD. Compared with the other MDs, DMD had
lower VCO2 throughout the A6MCT. There was no
difference in VCO2 during the A6MCT between
BMD, FSHD, and LGMD (Fig. 1B).
A6MCT HR. Throughout the A6MCT, DMD had a
lower HR than CTRL at minutes 2–6. In addition,
DMD HR during the A6MCT was lower than LGMD
at minutes 3–6, and lower than LGMD at minute 6.
BMD had a lower HR than CTRL at minute 6. There
was no difference in HR during the A6MCT between
LGMD, BMD, and FSHD (Fig. 1C).
A6MCT VE. Compared with CTRL, VE during the
A6MCT was lower in DMD at all time-points. In
BMD and LGMD, VE was lower than in CTRL at
minutes 2–6 of the A6MCT. FSHD VE was lower
than in CTRL at minutes 3–6 of the A6MCT. Within
the MD participants, DMD VE was lower than in
BMD at minutes 1 and 4, and lower than that in
LGMD and FSHD at all time-points of the A6MCT
(Fig. 1D).
A6MCT BLa. Pre-A6MCT BLa was not different
between groups (Table 2). After A6MCT, BLa was
lower in all MD groups compared with CTRL. Com-
pared with FSHD and LGMD, BLapost was lower in
DMD. Within-group changes in BLa from pre to
post were significant in all groups, except from
Table 2. Muscle, respiratory, and exercise performance
CTRL FSHD LGMD BMD DMD
Grip strength (kg) 44.9 (9.9) 25.9 (15.5)* 17.8 (9.8)* 9.7 (6.3)*,† 2.0 (2.6)*†‡
FEV1 (L) 4.12 (0.70) 2.79 (0.70)* 2.28 (0.79)* 3.21 (1.15) 0.88 (0.54)*
†‡§
FVC (L) 5.14 (0.95) 3.49 (0.92)* 2.95 (1.07)* 3.80 (1.42)* 1.13 (0.68))*†‡§
FEV1/FVC 0.81 (0.08) 0.81 (0.10) 0.78 (0.08) 0.85 (0.04) 0.82 (0.19)
A6MCT distance (km) 3.53 (0.11) 2.54 (0.44)* 2.39 (0.82)* 2.13 (0.80)* 0.45 (0.54))*†‡§
BLapre (mmol/L) 1.99 (0.90) 2.22 (0.70) 2.15 (0.79) 2.44 (1.80) 1.93 (0.58)
BLapost (mmol/L) 8.40 (3.02) 5.02 (2.10)* 5.03 (2.49)* 3.71 (1.38)* 2.17 (0.75)*
†§
Data are presented as mean (SD). CTRL, control; LGMD, limb girdle muscular dystrophy; FSHD, fascioscapulohumeral; BMD, Becker muscular dystrophy;
DMD, Duchenne muscular dystrophy; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; BLa, blood lactate; A6MCT, assisted 6-
minute cycle test.
*Significant difference vs. CTRL (P< 0.05).
†Significant difference vs. FSHD (P< 0.05).
‡Significant difference vs. BMD (P< 0.05).
§Significant difference vs. LGMD (P< 0.05).
4 Exercise in Muscular Dystrophy MUSCLE & NERVE Month 201830 Exercise in Muscular Dystrophy MUSCLE & NERV September
DMD, where there was no change in BLapre to
BLaPost.
Correlations. Within the pooled MD participants
(BMD, FSHD, and LGMD, n5 29), A6MCT distance
was correlated with handgrip strength (r5 0.609,
P< 0.05), FEV1 (r5 0.455, P< 0.05), FVC (r5 0.518,
P< 0.05), body fat percentage (r5 0.571, P< 0.05),
and BLapost (r5 0.437, P< 0.05). In terms of cardio-
respiratory measures during A6MCT, throughout
the final minute of exercise (others are omitted for
clarity), the A6MCT distance correlated with VO2
(r5 0.638, P< 0.05), VCO2 (r5 0.636, P< 0.05), HR
(r5 0.472, P< 0.05), and VE (r5 0.708, P< 0.05).
No correlations were observed for A6MCT distance
in other measures, including PASIPD, body mass,
body mass index, stature, lean mass, and biceps
thickness.
In CTRL, A6MCT distance correlated with
handgrip strength (r5 0.811) and biceps thickness
(r5 0.634). No other correlations were observed
for A6MCT distance in CTRL.
DISCUSSION
The main finding in this study is in agreement
with our hypothesis that A6MCT distance was lower
in adults with MD compared with CTRLs; in addi-
tion, adult males with DMD had a shorter A6MCT
distance than those with FSHD, BMD, and LGMD.
Within FSHD, BMD, and LGMD participants, the
variance in A6MCT distance could be attributed to
lung function (FEV1 and FVC); grip strength
(consistent with our hypothesis); and cardiorespira-
tory measures of VO2, VCO2, HR, and VE.
The A6MCT has previously been utilized in boys
with DMD.12,29,30 Although different hand bikes
were used, and earlier data were presented as total
revolutions,12,29 when estimated based on the dis-
tance achieved through 7-rpm passive cycling, our
present findings with adults (CTRL5 687–781 revo-
lutions) are similar to those presented previously
(CTRL boys 800 revolutions). Interestingly, boys
with DMD previously achieved 350 revolutions,12
whereas the estimated value in the present adult
DMD participants was lower (94 revolutions), consis-
tent with the progressive nature of DMD.
The lower A6MCT distance in the DMD partici-
pants, compared with FSHD, BMD, and LGMD, may
be attributed to the lower grip strength and lung
function, and to lower HR, VO2, VCO2, and VE
throughout the A6MCT. Although speculative based
on the present data, grip strength likely reflects the
recruitable muscle mass available to produce cycle
torque, and lung function reflects the ability of the
respiratory system to respond to the demands of
exercise stress. In DMD, there was minimal grip
strength and impaired lung function, and therefore
lower A6MCT distance. Further evidence for the
inability of adults with DMD to respond to an exer-
cise demand was supported by the lack of any meta-
bolic byproducts, with no change from BLapre to
BLapost.
The correlations in the FSHD, BMD, and LGMD
participants and physiological parameters suggest
FIGURE 1. Cardiorespiratory measures recorded during the assisted 6-minute cycle test. (A) Oxygen uptake (VO2). (B) Carbon diox-
ide output (VCO2). (C) Heart rate (HR). (D) Ventilation (VE). Asterisk: significant difference vs. all other groups (P<0.05); C: signifi-
cant difference from CTRL; F: significant difference from FSHD, B: significant difference from BMD; L: significant difference from
LGMD (all group differences are P<0.05). For clarity, significant differences from CTRL only are shown on the ventilation image. Data
are presented as mean (SD).
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that the A6MCT is a good measure of neuromuscu-
lar and cardiorespiratory function. It should be
noted that those measures with the highest correla-
tion (grip strength, VE, and VO2) could only
explain 40% of the variance in A6MCT. However,
the present correlations between the A6MCT and
physiological measures are similar to those observed
previously for the 6MWT and knee extension myo-
metry.7 Indeed, based on the previously reported
correlations between myometry and walking tasks
(r5 0.4–0.7), the 6MWT was advocated in MD as a
valid single measure of “cardiac, respiratory, circula-
tory, and muscular capacity.”7
In terms of its appropriateness in adults with
MD, none of the present adults with DMD and only
48% of the other adult MD participants could start a
6MWT. Similarly, validation testing of the A6MCT
(e.g., VO2peak) could only be completed in some of
these participants, and, beyond the grip strength
measures presented here, there are presently no
data comparing tests of upper limb function with
A6MCT distance. Previously, the A6MCT and 6MWT
were found to be in agreement (r5 0.65), with high
retest reliability for the A6MCT (ICC5 0.89, 95% CI
0.76–0.95).12 Therefore, the A6MCT previously vali-
dated in children with MD is an exercise test that
can be completed by adults with MD who are non-
ambulatory. Furthermore, in FSHD, BMD, and
LGMD, it represents a single measure that correlates
well with grip strength and lung function.
We observed no correlations between bicep
thickness and lean mass and A6MCT distance in the
pooled FSHD, LGMD, and BMD participants; this is
surprising as grip strength correlated with A6MCT
distance. The assessment of lean mass and biceps
thickness may therefore not reflect the recruitable
musculature in the MD participants. It is well estab-
lished that there is substantial remodeling of muscle
mass in MD,31 with infiltration of non-contractile
material, such that “pseudohypertrophy” is reported
in some MD muscles.32 It is likely that using more
stringent measures of assessment (e.g., MRI or
DXA), particularly in the upper limb, may have
reflected more closely the muscle mass available for
performing the A6MCT, as evidenced by the present
grip strength results. Within the CTRL group, where
one would assume the infiltration of non-contractile
material is lower than in those with MD, A6MCT dis-
tance correlated with biceps thickness (r5 0.634).
The associations in the MD participants between
A6MCT distance, grip strength, VO2, and BLapost all
suggest that recruitable muscle mass in the upper
limb contributes to A6MCT, despite not being
related to biceps thickness or lean mass in the pre-
sent study. Although the use of ultrasonography
may therefore be considered a limitation in our
study, due to lower limb contractures and the lack
of mobility in some of our more impaired MD par-
ticipants, MRI or DXA would have precluded their
inclusion.
We found no between group differences in cer-
tain outcome measures (e.g. grip strength), we
acknowledge that, in this study, but we acknowledge
that, due to the heterogeneity (and associated mea-
surement variance) of the participants within each
category, a greater number of participants would
have been beneficial. The paucity of data from adult
MD populations is such that the only previous data
on the primary outcome measure (A6MCT) is in
children with DMD vs. CTRL,12 where the effect size
(d5 2.42) results in a recommended group size of 2
(G*Power, Kiel, Germany). However, we do
acknowledge a limitation in the present study that
MD group differences may not be present in some
outcome measures due to type 2 error associated
with high variance. An example of this can be seen
for grip strength, where the coefficient of variation
was 55%–65% in LGMD, FSHD, and BMD, com-
pared with 22% in CTRL. This heterogeneity of out-
come measures is to be expected within MD, and is
likely to have contributed to the correlational find-
ings in the present study.
In conclusion, adult males with MD had a
shorter A6MCT distance than adult controls. Fur-
thermore, adult males with DMD had lower A6MCT
than those with FSHD, LGMD, and BMD. In adult
males with BMD, LGMD, and FSHD, the A6MCT
variance was attributable to grip strength and lung
function. The A6MCT can therefore be considered
an inclusive and physiologically meaningful test of
physical function for adults with MD.
Ethical Publication Statement: We (the authors) confirm that we
have read the Journal’s position on issues involved in ethical publi-
cation and affirm that this report is consistent with those
guidelines.
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